Non-Small Cell Lung Cancer Clinical Trial
Official title:
Time Trends in Diagnostic Delay and Waiting Times of Four Patient Cohorts, Diagnosed With Non-small Cell Lung Cancer, Treated With High Dose Radiotherapy.
A large group of non-small cell lung cancer patients is treated with radiotherapy. Delivery
of very high radiation doses is needed to obtain local control, but due to the large tumor
and nodal volume this is often impossible without causing unrepairable damage to the normal
tissue of the mediastinum, spinal cord, esophagus and lung.
Although every tumor is different with respect to the speed with which it grows and spreads,
it is obvious that time plays an important role in cancer therapy. Recently it was reported
that disease progression or increase of tumor volume occurred during the time interval
between diagnosis and treatment.(1, 2) This could lead to a less optimal radiation treatment
and consequently have an impact on overall survival. Moreover, the increasing number of
diagnostic procedures, aimed at obtaining more accurate information about the tumor
extension and biology, as well as the use of more sophisticated but labor intense radiation
techniques could prolong the time interval between clinical symptoms and the start of the
treatment. However, the influence of new diagnostic procedures or the applied radiotherapy
techniques on waiting times is not yet known. The investigators therefore want to
investigate 1) time trends in the waiting time for NSCLC patients, 2) the correlation
between waiting times and the use of more advanced diagnostic or therapeutic procedures, and
3) the correlation between waiting times and overall survival.
The hypotheses of the study:
1. The diagnostic delay for NSCLC patients has increased during the last 12 years.
2. The preparation time for radiotherapy of NSCLC patients has increased during the last
12 years.
3. Prolonged waiting times are associated with worse overall survival outcome.
A large group of non-small cell lung cancer patients is treated with radiotherapy. Delivery
of very high radiation doses is needed to obtain local control, but due to the large tumor
and nodal volume this is often impossible without causing unrepairable damage to the normal
tissue of the mediastinum, spinal cord, esophagus and lung.
Although every tumor is different with respect to the speed with which it grows and spreads,
it is obvious that time plays an important role in cancer therapy. Recently it was reported
that disease progression or increase of tumor volume occurred during the time interval
between diagnosis and treatment.(1, 2) This could lead to a less optimal radiation treatment
and consequently have an impact on overall survival. Moreover, the increasing number of
diagnostic procedures, aimed at obtaining more accurate information about the tumor
extension and biology, as well as the use of more sophisticated but labor intense radiation
techniques could prolong the time interval between clinical symptoms and the start of the
treatment. However, the influence of new diagnostic procedures or the applied radiotherapy
techniques on waiting times is not yet known. The investigators therefore want to
investigate 1) time trends in the waiting time for NSCLC patients, 2) the correlation
between waiting times and the use of more advanced diagnostic or therapeutic procedures, and
3) the correlation between waiting times and overall survival.
The hypotheses of the study:
1. The diagnostic delay for NSCLC patients has increased during the last 12 years.
2. The preparation time for radiotherapy of NSCLC patients has increased during the last
12 years.
3. Prolonged waiting times are associated with worse overall survival outcome.
The IKL collected data on waiting times and treatment of NSCLC patients treated in 2001 and
2004. These data will be used for this project. In addition, the MAASTRO lung database
contains information of patients treated in 2006 and 2010. Additional information about the
diagnostic procedure and radiation treatment preparation will be collected by reviewing the
patient charts. For this study a data request has to be submitted to the IKL and access to
MAASTRO patient data (charts and EMD) is needed.
The investigators aim to collect the following variables: Date of consultation
pulmonologist; Date of multidisciplinary meeting; Date of first consultancy at radiotherapy;
Date of start radiotherapy; Information about diagnostic procedure
(PET/CT/Pathology/EBUS/EUS); Information about RT procedure (3Dconventional/IMRT); General
patient characteristics; Overall survival
;
Observational Model: Cohort, Time Perspective: Retrospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03087448 -
Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1 | |
Recruiting |
NCT05042375 -
A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer
|
Phase 3 | |
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Terminated |
NCT05414123 -
A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
|
||
Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
Recruiting |
NCT05009836 -
Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03219970 -
Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.
|
||
Recruiting |
NCT05949619 -
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04054531 -
Study of KN046 With Chemotherapy in First Line Advanced NSCLC
|
Phase 2 | |
Withdrawn |
NCT03519958 -
Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong
|
||
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Terminated |
NCT02580708 -
Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01871805 -
A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1/Phase 2 | |
Terminated |
NCT04042480 -
A Study of SGN-CD228A in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05919641 -
LIVELUNG - Impact of CGA in Patients Diagnosed With Localized NSCLC Treated With SBRT
|
||
Completed |
NCT03656705 -
CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma
|
Phase 1 |